A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia

Blood

Volumn 113, Issue 7, 2009, Pages 1564-1573

  Heddle, Nancy M ^a,b   Cook, Richard J ^c   Tinmouth, Alan ^b,d   Kouroukis, C Tom ^a   Hervig, Tor ^e   Klapper, Ellen ^f   Brandwein, Joseph M ^g   Szczepiorkowski, Zbigniew M ^h   AuBuchon, James P ^h   Barty, Rebecca L ^a   Lee, Ker Ai ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL EXAMINATION; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

EID: 61849128781     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-178236     Document Type: Article

References (34)

1. Higby DJ, Cohen E, Holland JF, Sinks L. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion. 1974;14:440-446.
2. Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutel E. Platelet prophylaxis in acute non-lymphoblastic leukaemia [letter]. Lancet. 1978;1:267.
3. Murphy S, Litwin S, Herring LM, et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol. 1982;12:347-356.
4. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? Br J Haematol. 2005;131:588-595.
5. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66: 1105-1109.
6. Tinmouth AT, Freedman J. Prophylactic platelet transfusions: which dose is the best dose? a review of the literature. Transfus Med Rev. 2003;17: 181-193.
7. Heddle NM. Controversy concerning platelet dose. ISBT Science Series. 2007;2:220-225.
8. Norol F, Bierling P, Roudot-Thoraval F, et al. Platelet transfusion: a dose-response study. Blood. 1998;92:1448-1453.
9. Klumpp TR, Herman JH, Gaughan JP, et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, doubleblind trial. Transfusion. 1999;39;674-681.
10. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001;98:1346-1351.
11. TinmouthA, Tannock IF, Crump M, et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion. 2004;44:1711-1179.
12. Sensebé L, Giraudeau B, Bardiaux L, et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood. 2005;105:862-864.
13. Strauss RG. Low-dose prophylactic platelet transfusions: time for further study, but too early for routine clinical practice. Transfusion. 2004;44: 1680-1682.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
15. Fleiss J, Levin B, Paik M. Statistical Methods of Rates and Proportions, 3rd ed. New York, NY: Wiley; 2003.
16. Cox DR. Regression models and lifetimes (with discussion). J Royal Stat Soc B. 1972;34:187-220.
17. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
18. Cook RJ, Lawless JF. Marginal analysis of recurrent events and a terminating event. Stat Med. 1997;16:911-924.
19. Cook R, Lawless J. The Statistical Analysis of Recurrent Events. New York, NY: Springer; 2007.
20. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, 2nd ed. New York, NY: Wiley; 2002.
21. Lawless JF. Statistical Models and Methods for Lifetime Data, 2nd ed. New York, NY: Wiley; 2002.
22. Diggle P, Heagerty P, Liang K-Y, Zeger S. Analysis of Longitudinal Data. London, United Kingdom: Springer; 2002.
23. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870-1875.
24. Heddle NM, Cook RJ, Sigouin C, Slichter SJ, Murphy M, Rebulla P. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion. 2006;46:903-911.
25. Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher. 2006;21:78-84.
26. Kato T, Matsumoto A, Ogami K, Tahara T, Morita H, Miyazaki H. Native thrombopoietin: structure and function. Stem Cells. 1998;16:322-328.
27. Hervig T, Haugen T, Liseth K, Kjeldsen-Kragh J, Scott CS, Johannessen B. The platelet count accuracy of platelet concentrates obtained by using automated analysis is influenced by instrument bias and activated platelet components. Vox Sang. 2004;87:196-203.
28. Moroff G, Sowemimo-Coker SO, Finch S, et al. The influence of various hematology analyzers on component platelet counts. Transfus Med Rev. 2005;19:155-166.
29. Segal HC, Briggs C, Kunka S, et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol. 2005;128: 520-525.
30. Richa E, Krueger P, Burgstaler EA, Bryant SC, Winters JL. The effect of double- and triple-apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion. 2008;48:1325-1332.
31. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004; 104:1534-1541.
32. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18:153-167.
33. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocyto-penic patients with acute myeloid leukemia. Haematologica. 2006;91:1530-1537.
34. Nevo S, Fuller AK, Hartley E, Borinsky ME, Vogelsang GB. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 × 10(9) and 20 × 10(9) per L. Transfusion. 2007;47:801-812.